Published in Blood on July 20, 2015
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. J Clin Oncol (2016) 0.86
Risk organ + LCH gets the one-two punch? Blood (2015) 0.75
Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies. Immunotargets Ther (2016) 0.75
Salvage treatment of relapsed/refractory LCH. Blood Res (2016) 0.75
Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child. Int J Hematol (2017) 0.75
Optimal two-stage designs for phase II clinical trials. Control Clin Trials (1989) 21.03
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood (2007) 2.61
Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood (2013) 2.46
A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr (2001) 2.25
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med (2014) 2.23
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol (2014) 2.20
Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation. J Am Acad Dermatol (2014) 2.09
A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group. Arch Dis Child (1996) 1.81
Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer (2012) 1.60
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol (2002) 1.12
2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer (2009) 1.12
Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer (2005) 1.02
Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol (2002) 0.97
Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncol (2015) 0.96
Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer (2013) 0.96
A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer (2004) 0.96
Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant (2005) 0.90
Natural history of histiocytosis X: a Pediatric Oncology Group Study. Med Pediatr Oncol (1986) 0.88
Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant (2003) 0.87
Treatment of Langerhans cell histiocytosis with alpha-interferon. Lancet (1987) 0.86
Cyclosporine A therapy for multisystem langerhans cell histiocytosis. Med Pediatr Oncol (1999) 0.85
Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatr Blood Cancer (2012) 0.84
Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. J Pediatr Hematol Oncol (2009) 0.82
Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain. Pediatr Blood Cancer (2011) 0.82
Successful treatment of Langerhans'-cell histiocytosis with etanercept. N Engl J Med (2001) 0.81
Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis. Br J Haematol (2015) 0.81
[Cladribine for 13 cases refractory high-risk children Langerhans cell histiocytosis]. Zhonghua Xue Ye Xue Za Zhi (2014) 0.80
Langerhans cell histiocytosis, a case of Letterer Siwe disease. J La State Med Soc (2009) 0.80
Circulating cell-free BRAF(V600E) as a biomarker in children with Langerhans cell histiocytosis. Br J Haematol (2017) 0.75
Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. Br J Haematol (2017) 0.75